Rucaparib: Phase II started

Cancer Research UK began an open-label, dose-escalation, U.K. Phase II trial to evaluate rucaparib oral tablets for the first 7, 14 or 21 days of a 21-day cycle in about 38 patients. The trial will enroll patients with advanced breast or ovarian cancer with breast cancer 1 early onset (BRCA1) or BRCA2 mutations and those with advanced serious ovarian cancer but unknown BRCA status. Cancer Research said the oral tablet formulation replaces an earlier version of the trial, which was evaluating an IV formulation. ...